Physician profile
Richard G Eby
NPI 1598260325
$647.47
in general payments reported to CMS, 2019-2025
11 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.06 · 2022: $84.11 · 2023: $228 · 2024: $111 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $103.85 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $89.97 | 2022-2024 | Mounjaro |
| Novo Nordisk INC | $89.13 | 2022-2024 | Rybelsus, Ozempic, Saxenda |
| Insulet Corporation | $75.00 | 2025 | Omnipod |
| Sanofi Pasteur INC. | $72.58 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $60.77 | 2023-2025 | |
| Biogen, INC. | $52.23 | 2025 | Zurzuvae |
| Amgen INC. | $52.18 | 2024 | Evenity, Repatha |
| Pfizer INC. | $27.49 | 2022-2023 | |
| Abbott Laboratories | $12.21 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Eby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.